Please assess the completion status of the following clinical trial:

Trial Title: Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Stage 0-III breast cancer who are scheduled to receive endocrine therapy with tamoxifen or an aromatase inhibitor~* All prior surgery and chemotherapy should be complete~* Age 18 and above and postmenopausal~Exclusion Criteria:~* Major rheumatologic disorders~* Concomitant sex hormone containing drugs or Leutinizing Hormone Releasing Hormone agonist therapy~* For those subjects initiating treatment with an aromatase inhibitor, prior tamoxifen within 4 weeks of enrollment~* For those subjects initiating treatment with tamoxifen, prior aromatase inhibitor within 4 weeks of enrollment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AI therapy (Type: None): Subjects who started treatment with any of the three aromatase inhibitor (AI) medications
- Tamoxifen (Type: None): Subjects who started treatment with tamoxifen

Based on this trial design, predict the completion outcome and termination type (if applicable).